Company news

Radiopharm Theranostics Limited news in 2023

Radiopharm Theranostics Limited's news releases, calls and decks from 2023, newest first.

View company

2nd Australian site for Nanomab-PDL-1 Phase 1 trial

December 26, 2023

Phase 1 Therapeutic NSCLC (Lung Cancer) Trial Opens 4 Jan

December 21, 2023

Completion of Entitlement Offer

December 8, 2023

Radiopharm receives $4.85M R&D tax incentive

November 20, 2023

Entitlement Offer Documents

November 7, 2023

Entitlement Offer to raise approximately $10 million

October 30, 2023

FDA green light for diagnostic Phase 1 pancreatic trial

October 16, 2023

RAD receives approval for Phase 1 therapeutic study of NSCLC

October 8, 2023

Appendix 4E and FY23 Financial Report

August 31, 2023

TerThera Terbium-161 isotope supply agreement expanded

August 24, 2023

FDA Pre-IND meeting supports an IND application for RAD 101

May 29, 2023

RAD 301 receives FDA Orphan Drug Designation

May 9, 2023

Agreement with TerThera to supply Terbium-161 isotope

April 17, 2023

Radiopharm to acquire Pharma15 Corporation

March 2, 2023

Appendix 4D and Half Year Report

February 28, 2023

Radiopharm Theranostics initiates process for Nasdaq listing

February 13, 2023

Decks in 2023